Daily Heralds – Purdue Pharma, the controversial maker of OxyContin, and eyecare-pharmaceutical firm Ocular Therapeutix has announced a research partnership aiming to develop non-opioid pain treatments.
Read article
Business Law
For Olympic Athlete the Goal is Dual Degrees
The day before he ran the 2018 Hartford Half Marathon, Donn Cabral attended a seminar called “A Lawyer’s Primer on Blockchain.” After he won the race, he headed home to tackle a take-home exam for a course called “Motivating Individuals and Teams.”Continue Reading
Investors Won’t Tolerate Corporate Misdeeds, Inhumanity
Investment titan Amy Domini, widely considered a leading pioneer in socially responsible investing, came to UConn and shared what can only be described as good news.Continue Reading
Dean Mahoney ’09: A Passion for Entrepreneurship
Sometimes in business, and in life, you have to swallow your mistakes. Even if there are 700 of them!Continue Reading
Purdue Pharma grapples with growing protests
Congressional Committee Investigates Purdue Pharma
Beleaguered Purdue Pharma Makes Leadership Changes
Studying for the Bar? Put Down the Phone — Or Not
ABA Journal– The days of attending bar review classes in person are waning, say law school deans, and recent graduates preparing for the bar now do a great deal of studying on smartphones with offerings like streamed lectures, flashcard apps and even YouTube songs devoted to thinking through statutes and case law.
Purdue Pharma Faces Private-Sector Litigation
With Less Than 80 Days to Regulatory Deadline, Neo4j Urges Organizations to Turn GDPR Compliance Into Strategic Advantage
PR Newswire– In lead-up to GDPR’s looming May 25, 2018 deadline, Neo4j, the market leader in connected data, is urging any company that is investing in GDPR compliance to use those investments for a long-term, strategic advantage. As part of that effort, Neo4j is offering an interactive, personalized demonstration and solution assessment, which shows organizations how to use connected data to meet GDPR compliance, and also how to turn those compliance investments into a strategic advantage.